Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Provectus Stock News

PVCTOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

Provectus (PVCT) Forecast

News

Earnings Provectus (PVCT) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Provectus Stock News | OTC:PVCT | Benzinga

Get the latest news on Provectus stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Provectus performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, May 21, 2024

Provectus Biopharmaceuticals Presents Rose Be...
Benzinga Newsdesk

Tuesday, January 24, 2023

Short Volatility Alert: Provectus Biopharm
Christopher Sappo

Tuesday, January 17, 2023

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
Jad Malaeb - Sponsored

Wednesday, April 27, 2022

Several Companies Highlight Upcoming Presenta...
Benzinga Newsdesk

Tuesday, March 24, 2020

Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights

Wednesday, August 24, 2016

Provectus Biopharmaceuticals Proposes "Best E...
Benzinga
Provectus Biopharmaceuticals, Inc. Announces ...
Benzinga

Tuesday, August 23, 2016

Provectus Biopharma Announces Patent For Rose...
Benzinga

Monday, July 18, 2016

Provectus Biopharma Gets Patent For Halogenat...
Benzinga

Thursday, July 14, 2016

Provectus Biopharma Announces Austrailian Subsidiary Formed
Benzinga

Wednesday, July 13, 2016

Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting
Benzinga

Tuesday, July 12, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at ESMO 2016 Congress
Benzinga

Monday, June 13, 2016

Provectus Biopharmaceuticals Enters Stipulation Of Settlement In Shareholder Derivative Action
Benzinga

Tuesday, June 07, 2016

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology, Shows Disease Control Achieved In 63% Of Patients On 11.7 Month Follow Up
Benzinga

Thursday, May 19, 2016

Provectus Biopharma Reports Abstract Availabl...
Benzinga

Friday, April 22, 2016

Provectus Will Report Data on PV-10 in Combo Therapy, T-Cell Mediated Immunity at AACR Meeting
Benzinga
UPDATE: Provectus Says Presentation Showed Tr...
Benzinga
Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at AACR Annual Meeting 2016
Benzinga

Wednesday, March 30, 2016

Provectus Biopharma Reports Q4 Cash, Cash Equ...
Benzinga

Wednesday, March 16, 2016

Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma
Benzinga
Provectus Biopharmaceuticals Files Non-Timely...
Benzinga
Provectus Announces Results of Internal Investigation of Audit Committee
Benzinga

Monday, February 29, 2016

Provectus Biopharmaceuticals Says Initiates P...
Benzinga

Wednesday, January 20, 2016

Top Performing Industries For January 20, 2016
Benzinga

Tuesday, January 12, 2016

Provectus Biopharma Announces First Patents f...
Benzinga

Tuesday, September 29, 2015

Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation
Benzinga

Tuesday, August 18, 2015

Provectus Biopharmaceuticals Given US Patent Protecting Use of PV-10 as Part of Combination Therapy for Cancer
Benzinga

Wednesday, July 22, 2015

Provectus Biopharmaceuticals to Hold Q2 Business Update Conference Call on Thursday, August 6, 2015
Benzinga

Monday, July 06, 2015

Provectus Biopharmaceuticals' Phase 1 PV-10 Data on Liver Cancer Presented at 6th Asia-Pacific Primary Liver Cancer Expert Meeting
Benzinga

Thursday, July 02, 2015

Provectus Biopharma Reports Signing of Letter...
Benzinga

Wednesday, June 24, 2015

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 for Chemoablation of Liver Cancers at ESMO 17th World Congress on Gastrointestinal Cancer
Benzinga

Friday, June 19, 2015

Provectus Biopharma Prices Offering of 17.5M ...
Benzinga

Thursday, June 18, 2015

Provectus Biopharma Announces Intention Of Pu...
Benzinga

Monday, June 01, 2015

Provectus Biopharmaceuticals' Data on PV-10 as Intralesional Treatment of Melanoma Presented at 2015 American Society of Clinical Oncology Annual Meeting
Benzinga

Monday, May 18, 2015

Provectus Biopharmaceuticals Extends for 60 D...
Benzinga

Monday, April 20, 2015

Pfizer and Provectus Biopharmaceuticals Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer
Benzinga

Wednesday, April 15, 2015

Provectus Biopharmaceuticals Opens Patient Enrollment; Starts Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma
Benzinga

Thursday, March 12, 2015

Provectus Biopharmaceuticals Awarded PH-10 Patent by USPTO
Benzinga

Tuesday, January 27, 2015

Stocks With Unusual Volume For Jan 27: HQY, P...
Benzinga

Tuesday, December 23, 2014

Provectus Biopharmaceuticals' Protocol for Ph...
Benzinga

Monday, December 22, 2014

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed
Benzinga

Thursday, November 06, 2014

Provectus Biopharmaceuticals Submits PV-10 Ph...
Benzinga
Provectus Shares Halted News Pending
Benzinga

Tuesday, October 14, 2014

INC Research Signs Agreement to Perform FDA D...
Benzinga

Monday, September 29, 2014

Provectus Biopharmaceuticals Presents Data Showing Ablative, Bystander Effects of PV-10 at ESMO 2014
Benzinga

Monday, August 18, 2014

Provectus Biopharmaceuticals Enters into Non...
Benzinga

Tuesday, July 08, 2014

Provectus Biopharma Says it's In Position to Embark on Phase 3 Study of Intralesional PV-10 for Metastatic Melanoma
Benzinga

Tuesday, June 24, 2014

Provectus Biopharmaceuticals Shares Spike Lower; May be Attributed to Seeking Alpha Post
Benzinga

Thursday, June 12, 2014

Mid-Day Market Movers For Thursday, June 12, 2014
Benzinga
Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma
Benzinga

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved